PK Subtrial in Adolescent Patients With HAE Type I or II Participating in

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT06007677` - A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema	Phase 2
Completed	`NCT00997204` - EASSI - Evaluation of the Safety of Self-Administration With Icatibant	Phase 3
Completed	`NCT00438815` - Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks	Phase 3
Completed	`NCT00748202` - Berinert P Study of Subcutaneous Versus Intravenous Administration	Phase 3
Completed	`NCT01426763` - A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase	Phase 2
Terminated	`NCT04091113` - Hereditary Angioedema Kininogen Assay
Completed	`NCT00432510` - Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects	Phase 1
Completed	`NCT03712228` - A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)	Phase 2
Active, not recruiting	`NCT05453968` - Berotralstat Treatment in Children With Hereditary Angioedema	Phase 3
Recruiting	`NCT05505916` - An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)	Phase 3
Completed	`NCT02303626` - 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks	Phase 2/Phase 3
Not yet recruiting	`NCT02159430` - Hereditary AngioEdema, Neurobiology and Psychopathology	N/A
Completed	`NCT01984788` - Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE	Phase 2
Completed	`NCT04888650` - Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema
Completed	`NCT02448264` - First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers	Phase 1
Completed	`NCT05118958` - Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations	Phase 1
Completed	`NCT06414252` - Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients
Active, not recruiting	`NCT04739059` - Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks	Phase 3
Completed	`NCT02819102` - An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates	Phase 1
Completed	`NCT01679912` - A Call Center During HAE Attacks (SOS HAE)	Phase 4

NCT number	NCT05511922
Study type	Interventional
Source	KalVista Pharmaceuticals, Ltd.
Contact	KalVista Pharmaceuticals
Phone	1 (857) 999-0075
Email	clinicalstudies@kalvista.com
Status	Recruiting
Phase	Phase 3
Start date	October 24, 2022
Completion date	January 30, 2026

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms